HtrA Protease Family as Therapeutic Targets

Current Pharmaceutical Design

Volumn 19, Issue 6, 2013, Pages 977-1009

  Skorko Glonek, Joanna ^a   Zurawa Janicka, Dorota ^a   Koper, Tomasz ^a   Jarzab, Miroslaw ^a   Figaj, Donata ^a   Glaza, Przemyslaw ^a   Lipinska, Barbara ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

E. coli HtrA; HtrA activity regulation; HtrA and cell death; HtrA in cancer; HtrA in neurodegenerative diseases; HtrA of pathogenic bacteria; HtrA targeting

Indexed keywords

MITOCHONDRIAL PROTEIN; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE OMI;

ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; PARKINSON DISEASE; PROTEIN DEGRADATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MITOCHONDRIAL PROTEINS; PARKINSON DISEASE; PROTEASE INHIBITORS; PROTEOLYSIS; SERINE ENDOPEPTIDASES;

EID: 84877149937     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319060003     Document Type: Article

References (306)

1. Lipinska B, Fayet O, Baird L, Georgopoulos C. Identification, characterization, and mapping of the Escherichia coli htrA gene, whose product is essential for bacterial growth only at elevated temperatures. J Bacteriol 1989; 171: 1574-84.
2. Strauch KL, Beckwith J. An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins. Proc Natl Acad Sci USA 1988; 85: 1576-80.
3. Spiess C, Beil A, Ehrmann M. A temperature-dependent switch from chaperone to protease in a widely conserved heat shock pro-tein. Cell 1999; 97: 339-47.
4. Singh N, Kuppili RR, Bose K. The structural basis of mode of activation and functional diversity: A case study with HtrA family of serine proteases. Arch Biochem Biophys 2011; 516: 85-96.
5. Clausen T, Kaiser M, Huber R, Ehrmann M. HTRA proteases: regulated proteolysis in protein quality control. Nat Rev Mol Cell Biol 2011; 12: 152-62.
6. Krojer T, Sawa J, Huber R, Clausen T. HtrA proteases have a conserved activation mechanism that can be triggered by distinct molecular cues. Nat Struct Mol Biol 2010; 17: 844-852.
7. Zurawa-Janicka D, Kobiela J, Stefaniak T, et al. Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster. Acta Biochim Pol 2008; 55: 9-19.
8. Vogt SL, Nevesinjac AZ, Humphries RM, Donnenberg MS, Arm-strong GD, Raivio TL. The Cpx envelope stress response both facilitates and inhibits elaboration of the enteropathogenic Escherichia coli bundle-forming pilus. Mol Microbiol 2010; 76: 1095-110.
9. Baud C, Hodak H, Willery E, et al. Role of DegP for two-partner secretion in Bordetella. Mol Microbiol 2009; 74: 315-29.
10. Rigoulay C, Entenza JM, Halpern D, et al. Comparative analysis of the roles of HtrA-like surface proteases in two virulent Staphylo-coccus aureus strains. Infect Immun 2005; 73: 563-72.
11. Hoy B, Lower M, Weydig C, et al. Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt in-tercellular adhesion. EMBO Rep 2010; 11: 798-804.
12. Hoy B, Geppert T, Boehm M, et al. Distinct roles of secreted HtrA proteases from gram-negative pathogens in cleaving the junctional protein and tumor suppressor E-cadherin. J Biol Chem 2012; 287: 10115-20.
13. Zurawa-Janicka D, Skorko-Glonek J, Lipinska B. HtrA proteins as targets in therapy of cancer and other diseases. Expert Opin Ther Targets 2010; 14: 665-79.
14. Hegde R, Srinivasula SM, Zhang Z, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that dis-rupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277: 432-38.
15. Martins LM, Iaccarino I, Tenev T, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002; 277: 439-44.
16. Verhagen AM, Silke J, Ekert PG, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize in-hibitor of apoptosis proteins. J Biol Chem 2002; 277: 445-54.
17. Chien J, Staub J, Hu S-I, et al. A candidate tumor suppressor HtrA1 is down-regulated in ovarian cancer. Oncogene 2004; 23: 1636-44.
18. Chien J, Aletti G, Baldi A, et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006; 116: 1994-2004.
19. He X, Ota T, Liu P, Su C, Chien J, Shridhar V. Downregulation of HtrA1 Promotes Resistance to Anoikis and Peritoneal Dissemina-tion of Ovarian Cancer Cells. Cancer Res 2010; 70: 3109-18.
20. Chien J, Campioni M, Shridhar V, Baldi A. HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 2009; 9: 451-68.
21. Shiga A, Nozaki H, Yokoseki A, et al. Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-β1 via cleavage of proTGF-β1. Hum Mol Genet 2011; 20: 1800-10.
22. Jones JM, Datta P, Srinivasula SM, et al. Loss of Omi mitochon-drial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003; 425: 721-7.
23. Martins LM, Morrison A, Klupsch K, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24: 9848-62.
24. Krick S, Shi S, Ju W, et al. Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease. Proc Natl Acad Sci USA 2008; 105: 14106-11.
25. Jin S, Kalkum M, Overholtzer M, Stoffel A, Chait BT, Levine AJ. CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals. Genes Dev 2003; 17: 359-67.
26. Trencia A, Fiory F, Maitan MA, et al. Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15. J Biol Chem 2004; 279: 46566-72.
27. Liu MJ, Liu ML, Shen YF, et al. Transgenic mice with neuron-specific overexpression of HtrA2/Omi suggest a neuroprotective role for HtrA2/Omi. Biochem Biophys Res Commun 2007; 362: 295-300.
28. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 2008; 15: 453-60.
29. Bhuiyan MS, Fukunaga K. Mitochondrial serine protease HtrA2/Omi as a potential therapeutic target. Curr Drug Targets 2009; 10: 372-83.
30. Liu Z, Li H, Derouet M, Berezkin A, Sasazuki T, Shirasawa S, Rosen K. Oncogenic Ras inhibits anoikis of intestinal epithelial cells by preventing the release of a mitochondrial pro-apoptotic protein Omi/HtrA2 into the cytoplasm. J Biol Chem 2006; 281: 14738-47
31. Okada M, Adachi S, Imai T, et al. A novel mechanism for imatinib mesylate–induced cell death of BCR-ABL-positive human leuke-mic cells caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004; 103: 2299-307.
32. Chien J. WT1 as a substrate of HtrA2: a potential pathway for therapeutic targeting by HtrA proteases. Future Oncol 2010; 6: 1233-5.
33. Dagda RK, Chu CT. Mitochondrial quality control: insights on how Parkinson’s disease related genes PINK1, Parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. J Bioenerg Biomembr 2009; 41: 473-479.
34. De Castro IP, Martins LM, Loh SH. Mitochondrial quality control and Parkinson's disease: a pathway unfolds. Mol Neurobiol 2011; 43: 80-6.
35. Gupta S, Singh R, Datta P, et al. The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity. J Biol Chem 2004; 279: 45844-54.
36. Behbahani H, Pavlov PF, Wiehager B, Nishimura T, Winblad B. Association of Omi/HtrA2 with γ-secretase in mitochondria. Neurochem Int 2010; 57: 668-75.
37. Park HJ, Kim SS, Seong YM, et al. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J Biol Chem 2006; 281: 34277-87.
38. Park HJ, Seong YM, Choi JY, Kang S, Rhim H. Alzheimer's dis-ease-associated amyloid beta interacts with the human serine prote-ase HtrA2/Omi. Neurosci Lett 2004; 357: 63-7.
39. Kooistra J, Milojevic J, Melacini G, Ortega J. A new function of human HtrA2 as an amyloid-beta oligomerization inhibitor. J Alz-heimers Dis 2009; 17: 281-94.
40. Nie GY, Hampton A, Li Y, Findlaz JK, Salamonsen LA. Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem J 2003; 371: 39-48.
41. Nie G, Li Y, He H, Findlay JK, Salamonsen LA. HtrA3, a serine protease possessing an IGF-binding domain, is selectively expressed at the maternal-fetal interface during placentation in the mouse. Placenta 2006; 27: 491-501.
42. Singh H, Makino S, Endo Y, Nie G. Inhibition of HTRA3 stimulates trophoblast invasion during human placental development. Placenta 2010; 31: 1085-92.
43. Singh H, Endo Y, Nie G. Decidual HtrA3 negatively regulates trophoblast invasion during human placentation. Hum Reprod 2011; 26: 748-57.
44. Beleford D, Liu Z, Rattan R, Quagliuolo L, Boccellino M, Baldi A, Maguire J, Staub J, Molina J, Shridhar V. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res 2010; 16: 398-409.
45. Beleford D, Rattan R, Chien J, Shridhar V. High-temperature requirement A3 (HtrA3) promotes etoposide-and cisplatin-induced cytotoxicity in lung cancer cell lines. J Biol Chem 2010; 285: 12011-27.
46. Oka C, Tsujimoto R, Kajikawa M, et al. HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 2004; 131(5): 1041-53.
47. Tocharus J, Tsuchiya A, Kajikawa M, Ueta Y, Oka C, Kawaichi M. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-beta signaling. Dev Growth Differ 2004; 46: 257-74.
48. Krojer T, Garrido-Franco M, Huber R, Ehrmann M, Clausen T. Crystal structure of DegP (HtrA) reveals a new protease-chaperone machine. Nature 2002; 416: 455-9.
49. Wilken C, Kitzing K, Kurzbauer R, Ehrmann M, Clausen T. Crystal structure of the DegS stress sensor: How a PDZ domain recog-nizes misfolded protein and activates a protease. Cell 2004; 117: 483-94.
50. Zeth K. Structural analysis of DegS, a stress sensor of the bacterial periplasm. FEBS Lett 2004; 569: 351-8.
51. Wrase R, Scott H, Hilgenfeld R, Hansen G. The Legionella HtrA homolog DegQ is a self-compartmentizing protease that forms large 12-meric assemblies. Proc Natl Acad Sci USA 2011; 108: 10490-5.
52. Mohamedmohaideen NN, Palaninathan SK, Morin PM, et al. Structure and function of the virulence-associated high-temperature requirement A of Mycobacterium tuberculosis. Biochemistry 2008; 47: 6092-102.
53. Truebestein L, Tennstaedt A, Mönig T, et al. Substrate-induced remodeling of the active site regulates human HTRA1 activity. Nat Struct Mol Biol 2011; 18: 386-8.
54. Eigenbrot C, Ultsch M, Lipari MT, et al. Structural and Functional Analysis of HtrA1 and Its Subdomains. Structure 2012 May 9. [Epub ahead of print]
55. Li W, Srinivasula SM, Chai J, et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol 2002; 9: 436-41.
56. Runyon ST, Zhang Y, Appleton BA, et al. Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. Protein Sci 2007; 16: 2454-71.
57. Skorko-Glonek J, Zurawa D, Kuczwara E, Wozniak M, Wypych Z, Lipinska B. The Escherichia coli heat shock protease HtrA participates in defense against oxidative stress. Mol Gen Genet 1999; 262: 342-50.
58. Misra R, CastilloKeller M, Deng M. Overexpression of protease-deficient DegP(S210A) rescues the lethal phenotype of Escherichia coli OmpF assembly mutants in a degP background. J Bacteriol 2000; 182: 4882-8.
59. Clausen T, Southan C, Ehrmann M. The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell 2002; 10: 443-55.
60. Jiang J, Zhang X, Chen Y, et al. Activation of DegP chaperone-protease via formation of large cage-like oligomers upon binding to substrate proteins. Proc Natl Acad Sci USA 2008; 105: 11939-44.
61. Krojer T, Sawa J, Schafer E, Saibil HR, Ehrmann M, Clausen T. Structural basis for the regulated protease and chaperone function of DegP. Nature 2008; 453: 885-90.
62. Shen QT, Bai XC, Chang LF, Wu Y, Wang HW, Sui SF. Bowl-shaped oligomeric structures on membranes as DegP's new functional forms in protein quality control. Proc Natl Acad Sci USA 2009; 106: 4858-63.
63. Iwanczyk J, Damjanovic D, Kooistra J, et al. Role of the PDZ domains in Escherichia coli DegP protein. J Bacteriol 2007; 189: 3176-86.
64. Hung AY, Sheng M. PDZ domains: structural modules for protein complex assembly. J Biol Chem 2002; 277: 5699-702.
65. Kim S, Grant RA, Sauer RT. Covalent linkage of distinct substrate degrons controls assembly and disassembly of DegP proteolytic cages. Cell 2011; 145: 67-78.
66. Lipinska B, Zylicz M, Georgopoulos C. The HtrA (DegP) protein, essential for Escherichia coli survival at high temperatures, is an endopeptidase. J Bacteriol 1990; 172: 1791-7.
67. Hauske P, Meltzer M, Ottmann C, et al. Selectivity profiling of DegP substrates and inhibitors. Bioorg Med Chem 2009; 17: 2920-4.
68. Skorko-Glonek J, Wawrzynow A, Krzewski K, Kurpierz K, Lipin-ska B. Site-directed mutagenesis of the HtrA (DegP) serine prote-ase, whose proteolytic activity is indispensable for Escherichia coli survival at elevated temperatures. Gene 1995; 163: 47-52.
69. Laskowska E, Kuczynska-Wisnik D, Skorko-Glonek J, Taylor A. Degradation by proteases Lon, Clp and HtrA, of Escherichia coli proteins aggregated in vivo by heat shock; HtrA protease action in vivo and in vitro. Mol Microbiol 1996; 22: 555-71.
70. Baneyx F, Georgiou G. Construction and characterization of Escherichia coli strains deficient in multiple secreted proteases: pro-tease III degrades high-molecular-weight substrates in vivo. J Bac-teriol 1991; 173: 2696-703.
71. Betton JM, Sassoon N, Hofnung M, Laurent M. Degradation versus aggregation of misfolded maltose-binding protein in the periplasm of Escherichia coli. J Biol Chem 1998; 273: 8897-902.
72. Sone M, Kishigami S, Yoshihisa T, Ito K. Roles of disulfide bonds in bacterial alkaline phosphatase. J Biol Chem 1997; 272: 6174-8.
73. CastilloKeller M, Misra R. Protease-deficient DegP suppresses lethal effects of a mutant OmpC protein by its capture. J Bacteriol 2003; 185: 148-54.
74. Jones CH, Dexter P, Evans AK, Liu C, Hultgren SJ, Hruby DE. Escherichia coli DegP protease cleaves between paired hydropho-bic residues in a natural substrate: the PapA pilin. J Bacteriol 2002; 184: 5762-71.
75. Kim KI, Park SC, Kang SH, Cheong GW, Chung CH. Selective degradation of unfolded proteins by the self-compartmentalizing HtrA protease, a periplasmic heat shock protein in Escherichia coli. J Mol Biol 1999; 294: 1363-74.
76. Skorko-Glonek J, Zurawa D, Tanfani F, et al. The N-terminal region of HtrA heat shock protease from Escherichia coli is essential for stabilization of HtrA primary structure and maintaining of its oligomeric structure. Biochim Biophys Acta 2003; 1649: 171-82.
77. Cavard D. Role of DegP protease on levels of various forms of colicin A lysis protein. FEMS Microbiol Lett 1995; 125: 173-8.
78. Isaac DD, Pinkner JS, Hultgren SJ, Silhavy TJ. The extracytoplas-mic adaptor protein CpxP is degraded with substrate by DegP. Proc Natl Acad Sci USA 2005; 102: 17775-9.
79. Kolmar H, Waller PR, Sauer RT. The DegP and DegQ periplasmic endoproteases of Escherichia coli: specificity for cleavage sites and substrate conformation. J Bacteriol 1996; 178: 5925-9.
80. Jomaa A, Damjanovic D, Leong V, Ghirlando R, Iwanczyk J, Ortega J. The inner cavity of Escherichia coli DegP protein is not essential for molecular chaperone and proteolytic activity. J Bacteriol 2007; 189: 706-16.
81. Krojer T, Pangerl K, Kurt J, et al. Interplay of PDZ and protease domain of DegP ensures efficient elimination of misfolded pro-teins. Proc Natl Acad Sci USA 2008; 105: 7702-7.
82. Sobiecka-Szkatula A, Polit A, Scire A, et al. Temperature-induced conformational changes within the regulatory loops L1-L2-LA of the HtrA heat-shock protease from Escherichia coli. Biochim Biophys Acta 2009; 1794: 1573-82.
83. Skorko-Glonek J, Laskowska E, Sobiecka-Szkatula A, Lipinska B. Characterization of the chaperone-like activity of HtrA (DegP) protein from Escherichia coli under the conditions of heat shock. Arch Biochem Biophys 2007; 464: 80-9.
84. Rizzitello AE, Harper JR, Silhavy TJ. Genetic evidence for parallel pathways of chaperone activity in the periplasm of Escherichia coli. J Bacteriol 2001; 183: 6794-800.
85. Bass S, Gu Q, Christen A. Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R1pA. J Bacteriol 1996; 178: 1154-61.
86. Waller PR, Sauer RT. Characterization of degQ and degS, Escherichia coli genes encoding homologs of the DegP protease. J Bacteriol 1996; 178: 1146-53.
87. Sawa J, Malet H, Krojer T, Canellas F, Ehrmann M, Clausen T. Molecular adaptation of the DegQ protease to exert protein quality control in the bacterial cell envelope. J Biol Chem 2011; 286: 30680-90.
88. Bai XC, Pan XJ, Wang XJ, et al. Characterization of the structure and function of Escherichia coli DegQ as a representative of the DegQ-like proteases of bacterial HtrA family proteins. Structure 2011; 19: 1328-37.
89. Malet H, Canellas F, Sawa J, et al. Newly folded substrates inside the molecular cage of the HtrA chaperone DegQ. Nat Struct Mol Biol 2012; 19: 152-7.
90. Yan N, Shi Y. Allosteric activation of a bacterial stress sensor. Cell 2007; 131: 441-3.
91. Walsh NP, Alba BM, Bose B, Gross CA, Sauer RT. OMP peptide signals initiate the envelope-stress response by activating DegS protease via relief of inhibition mediated by its PDZ domain. Cell 2003; 113: 61-71.
92. Sohn J, Sauer RT. OMP peptides modulate the activity of DegS protease by differential binding to active and inactive conforma-tions. Mol Cell 2009; 33: 64-74.
93. Sohn J, Grant RA, Sauer RT. Allosteric activation of DegS, a stress sensor PDZ protease. Cell 2007; 131: 572-83.
94. Kaper JB. Pathogenic Escherichia coli. Int J Med Microbiol 2005; 295: 355-6.
95. Redford P, Roesch PL, Welch RA. DegS is necessary for virulence and is among extraintestinal Escherichia coli genes induced in murine peritonitis. Infect Immun 2003; 71: 3088-96.
96. Redford P, Welch RA. Role of sigma E-regulated genes in Escherichia coli uropathogenesis. Infect Immun 2006; 74: 4030-8.
97. Bringer MA, Barnich N, Glasser AL, Bardot O, Darfeuille-Michaud A. HtrA stress protein is involved in intramacrophagic replication of adherent and invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect Immun 2005; 73: 712-21.
98. Kim DY, Kim KK. Structure and function of HtrA family proteins, the key players in protein quality control. J Biochem Mol Biol 2005; 38: 266-74.
99. Onder O, Turkarslan S, Sun D, Daldal F. Overproduction or absence of the periplasmic protease DegP severely compromises bacterial growth in the absence of the dithiol: disulfide oxidoreductase DsbA. Mol Cell Proteomics 2008; 7: 875-90.
100. Locht C, Antoine R, Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr Opin Microbiol 2001; 4: 82-9.
101. Hodak H, Clantin B, Willery E, Villeret V, Locht C, Jacob-Dubuisson F. Secretion signal of the filamentous haemagglutinin, a model two-partner secretion substrate. Mol Microbiol 2006; 61: 368-82.
102. Flannagan RS, Aubert D, Kooi C, Sokol PA, Valvano MA. Burk-holderia cenocepacia requires a periplasmic HtrA protease for growth under thermal and osmotic stress and for survival in vivo. Infect Immun 2007; 75: 1679-89.
103. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001; 32: 1201-6.
104. Humphrey T, O'Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production perspective. Int J Food Microbiol 2007; 117: 237-57.
105. Beery JT, Hugdahl MB, Doyle MP. Colonization of gastrointestinal tracts of chicks by Campylobacter jejuni. Appl Environ Microbiol 1988; 54: 2365-70.
106. Baek KT, Vegge CS, Skorko-Glonek J, Brondsted L. Different contributions of HtrA protease and chaperone activities to Campy-lobacter jejuni stress tolerance and physiology. Appl Environ Microbiol 2011; 77: 57-66.
107. Brondsted L, Andersen MT, Parker M, Jorgensen K, Ingmer H. The HtrA protease of Campylobacter jejuni is required for heat and oxygen tolerance and for optimal interaction with human epithelial cells. Appl Environ Microbiol 2005; 71: 3205-12.
108. Baek KT, Vegge CS, Brondsted L. HtrA chaperone activity contributes to host cell binding in Campylobacter jejuni. Gut Pathog 2011; 3: 13.
109. Boehm M, Hoy B, Rohde M, et al. Rapid paracellular transmigra-tion of Campylobacter jejuni across polarized epithelial cells with-out affecting TER: role of proteolytic-active HtrA cleaving E-cadherin but not fibronectin. Gut Pathog 2012; 4: 3.
110. Boer P, Wagenaar JA, Achterberg RP, Putten JP, Schouls LM, Duim B. Generation of Campylobacter jejuni genetic diversity in vivo. Mol. Microbiol 2002; 44: 351-9.
111. Cortes G, de Astorza B, Benedi VJ, Alberti S. Role of the htrA gene in Klebsiella pneumoniae virulence. Infect Immun 2002; 70: 4772-6.
112. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15: 506-26.
113. Pedersen LL, Radulic M, Doric M, Abu Kwaik Y. HtrA homolog of Legionella pneumophila: an indispensable element for intracellular infection of mammalian but not protozoan cells. Infect Immun 2001; 69: 2569-79.
114. Yuan L, Rodrigues PH, Belanger M, Dunn WA, Jr., Progulske-Fox A. Porphyromonas gingivalis htrA is involved in cellular invasion and in vivo survival. Microbiology 2008; 154: 1161-9.
115. Roy F, Vanterpool E, Fletcher HM. HtrA in Porphyromonas gin-givalis can regulate growth and gingipain activity under stressful environmental conditions. Microbiology 2006; 152: 3391-8.
116. Boucher JC, Martinez-Salazar J, Schurr MJ, Mudd MH, Yu H, Deretic V. Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA. J Bacteriol 1996; 178: 511-23.
117. Yorgey P, Rahme LG, Tan MW, Ausubel FM. The roles of mucD and alginate in the virulence of Pseudomonas aeruginosa in plants, nematodes and mice. Mol Microbiol 2001; 41: 1063-76.
118. Thompson JA, Helaine S, Holden DW. The Salmonella-mouse interaction: a versatile model to study bacterial infection. In: San-sonetti S. Ed. Bacterial virulence: basic principles, models and global approaches. Wiley-Blacwell. Wiley-VCH Verlag GmbH&Co. KgaA 2010; pp. 139-64.
119. Mo E, Peters SE, Willers C, Maskell DJ, Charles IG. Single, dou-ble and triple mutants of Salmonella enterica serovar Typhimurium degP (htrA), degQ (hhoA) and degS (hhoB) have diverse pheno-types on exposure to elevated temperature and their growth in vivo is attenuated to different extents. Microb Pathog 2006; 41: 174-82.
120. Humphreys S, Stevenson A, Bacon A, Weinhardt AB, Roberts M. The alternative sigma factor, sigmaE, is critically important for the virulence of Salmonella typhimurium. Infect Immun 1999; 67: 1560-8.
121. Johnson K, Charles I, Dougan G, et al. The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol 1991; 5: 401-7.
122. Everest P, Frankel G, Li J, Lund P, Chatfield S, Dougan G. Expression of LacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol Lett 1995; 126: 97-9101.
123. Lewis C, Skovierova H, Rowley G, et al. Salmonella enterica Serovar Typhimurium HtrA: regulation of expression and role of the chaperone and protease activities during infection. Microbiology 2009; 155: 873-81.
124. Williams K, Oyston PC, Dorrell N, Li S, Titball RW, Wren BW. Investigation into the role of the serine protease HtrA in Yersinia pestis pathogenesis. FEMS Microbiol Lett 2000; 186: 281-6.
125. Phillips RW, Roop RM. Brucella abortus HtrA functions as an authentic stress response protease but is not required for wild-type virulence in BALB/c mice. Infect Immun 2001; 69: 5911-3.
126. Galindo CL, Sha J, Moen ST, et al. Comparative Global Gene Expression Profiles of Wild-Type Yersinia pestis CO92 and Its Braun Lipoprotein Mutant at Flea and Human Body Temperatures. Comp Funct Genomics 2010. doi:10.1155/2010/342168.
127. Jones CH, Bolken TC, Jones KF, Zeller GO, Hruby DE. Conserved DegP protease in gram-positive bacteria is essential for thermal and oxidative tolerance and full virulence in Streptococcus pyogenes. Infect Immun 2001; 69: 5538-45.
128. Biswas S, Biswas I. Role of HtrA in surface protein expression and biofilm formation by Streptococcus mutans. Infect Immun 2005; 73: 6923-34.
129. Wilson RL, Brown LL, Kirkwood-Watts D, et al. Listeria monocy-togenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun 2006; 74: 765-8.
130. Ibrahim YM, Kerr AR, McCluskey J, Mitchell TJ. Role of HtrA in the virulence and competence of Streptococcus pneumoniae. Infect Immun 2004; 72: 3584-91.
131. Stack HM, Sleator RD, Bowers M, Hill C, Gahan CG. Role for HtrA in stress induction and virulence potential in Listeria monocy-togenes. Appl Environ Microbiol 2005; 71: 4241-7.
132. Wonderling LD, Wilkinson BJ, Bayles DO. The htrA (degP) gene of Listeria monocytogenes 10403S is essential for optimal growth under stress conditions. Appl Environ Microbiol 2004; 70: 1935-43.
133. White MJ, He H, Penoske RM, Twining SS, Zahrt TC. PepD participates in the mycobacterial stress response mediated through MprAB and SigE. J Bacteriol 2010; 192: 1498-510.
134. Schluger NW, Rom WN. The host immune response to tuberculo-sis. Am J Respir Crit Care Med 1998; 157: 679-91.
135. Xiong Y, Chalmers MJ, Gao FP, Cross TA, Marshall AG. Identification of Mycobacterium tuberculosis H37Rv integral membrane proteins by one-dimensional gel electrophoresis and liquid chroma-tography electrospray ionization tandem mass spectrometry. J Pro-teome Res 2005; 4: 855-61.
136. Skeiky YA, Lodes MJ, Guderian JA, et al. Cloning, expression, and immunological evaluation of two putative secreted serine pro-tease antigens of Mycobacterium tuberculosis. Infect Immun 1999; 67: 3998-4007.
137. Braunstein M, Griffin TI, Kriakov JI, Friedman ST, Grindley ND, Jacobs WR, Jr. Identification of genes encoding exported Mycobac-terium tuberculosis proteins using a Tn552'phoA in vitro transposi-tion system. J Bacteriol 2000; 182: 2732-40.
138. White MJ, Savaryn JP, Bretl DJ, et al. The HtrA-like serine prote-ase PepD interacts with and modulates the Mycobacterium tuberculosis 35-kDa antigen outer envelope protein. PLoS One 2011; 6.
139. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-56.
140. Sebert ME, Palmer LM, Rosenberg M, Weiser JN. Microarray-based identification of htrA, a Streptococcus pneumoniae gene that is regulated by the CiaRH two-component system and contributes to nasopharyngeal colonization. Infect Immun 2002; 70: 4059-67.
141. Dawid S, Sebert ME, Weiser JN. Bacteriocin activity of Streptococcus pneumoniae is controlled by the serine protease HtrA via posttranscriptional regulation. J Bacteriol 2009; 191: 1509-18.
142. Sebert ME, Patel KP, Plotnick M, Weiser JN. Pneumococcal HtrA protease mediates inhibition of competence by the CiaRH two-component signaling system. J Bacteriol 2005; 187: 3969-79.
143. Tsui HC, Keen SK, Sham LT, Wayne KJ, Winkler ME. Dynamic distribution of the SecA and SecY translocase subunits and septal localization of the HtrA surface chaperone/protease during Streptococcus pneumoniae D39 cell division. MBio 2011; 2.
144. Ahn S-J, Lemos JAC, Burne RA. Role of HtrA in growth and competence of Streptococcus mutans UA159. J Bacteriol 2005; 187: 3028-38.
145. Kang K-h, Lee J-S, Yoo M, Jin I. The influence of HtrA expression on the growth of Streptococcus mutans during acid stress. Mol Cells 2010; 29: 297-304.
146. Lyon WR, Caparon MG. Role for serine protease HtrA (DegP) of Streptococcus pyogenes in the biogenesis of virulence factors SpeB and the hemolysin streptolysin S. Infect Immun 2004; 72: 1618-25.
147. Cole JN, Aquilina JA, Hains PG, et al. Role of group A Streptococcus HtrA in the maturation of SpeB protease. Proteomics 2007; 7: 4488-98.
148. Koehler TM. Bacillus anthracis physiology and genetics. Mol Aspects Med 2009; 30: 386-96.
149. Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A. Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol 2009; 75: 6157-67.
150. Chitlaru T, Zaide G, Ehrlich S, Inbar I, Cohen O, Shafferman A. HtrA is a major virulence determinant of Bacillus anthracis. Mol Microbiol 2011; 81: 1542-59.
151. Welkos SL, Bozue JA, Cote CK. The interaction between Bacillus anthracis and macrophages. In: Bergman NH. Ed. Bacillus an-thracis and Anthrax. Hoboken, NJ: John Wiley & Sons 2011; pp.179-208.
152. 2-dependent cross talk mechanisms modulate extracellular proteolytic activities. J Bacteriol 2006; 188: 3551-71.
153. Land JA, Van Bergen JE, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010; 16: 189-204.
154. Zhong G. Chlamydia trachomatis secretion of proteases for ma-nipulating host signaling pathways. Front Microbiol 2011; 2: 14.
155. Zhong G, Lei L, Gong S, Lu C, Qi M, Chen D. Chlamydia-secreted proteins in chlamydial interactions with host cells. Curr Chem Biol 2011; 5: 29-37.
156. Wu X, Lei L, Gong S, Chen D, Flores R, Zhong G. The chlamydial periplasmic stress response serine protease cHtrA is secreted into host cell cytosol. BMC Microbiol 2011; 11: 87-7.
157. Huston WM, Theodoropoulos C, Mathews SA, Timms P. Chlamy-dia trachomatis responds to heat shock, penicillin induced persis-tence, and IFN-gamma persistence by altering levels of the extracy-toplasmic stress response protease HtrA. BMC Microbiol 2008; 8: 190.
158. Huston WM, Tyndall JD, Lott WB, Stansfield SH, Timms P. Unique residues involved in activation of the multitasking prote-ase/chaperone HtrA from Chlamydia trachomatis. PLoS One 2011; 6: e24547.
159. Rieder G, Fischer W, Haas R. Interaction of Helicobacter pylori with host cells: function of secreted and translocated molecules. Curr Opin Microbiol 2005; 8: 67-73.
160. Necchi V, Candusso ME, Tava F, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007; 132: 1009-23.
161. Papini E, Satin B, Norais N, et al. Selective increase of the perme-ability of polarized epithelial cell monolayers by Helicobacter py-lori vacuolating toxin. J Clin Invest 1998; 102: 813-20.
162. Wroblewski LE, Shen L, Ogden S, et al. Helicobacter pylori dys-regulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology 2009; 136: 236-46.
163. Huang CH, Chiou SH. Proteomic analysis of upregulated proteins in Helicobacter pylori under oxidative stress induced by hydrogen peroxide. Kaohsiung J Med Sci 2011; 27: 544-53.
164. Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 2010; 74: 81-94.
165. Zumbrumm J, Treub B. Primary structure of a putative serine pro-tease specific for IGF-binding proteins. FEBS Lett 1996; 398: 187-92.
166. De Luca A, De Falco M, Severino A, et al. Distribution of the Serine Protease HtrA1 in Normal Human Tissues. J Histochem Cy-tochem 2003; 51: 1279-84.
167. Murwantoko, Yano M, Ueta Y, et al. Binding of proteins to the PDZ domain regulates proteolytic activity of HtrA1 serine prote-ase. Biochem J 2004; 381: 895-904.
168. Launay S, Maubert E, Lebeurrier A, et al. HtrA1-dependent prote-olysis of TGF-β controls both neuronal maturation and development survival. Cell Death Differ 2008; 15: 1408-16.
169. Gilicze A, Kohalmi B, Pocza P, et al. HtrA1 is a novel mast cell serine protease of mice and men. Mol Immunol 2007; 44: 2961-8.
170. Clawson GA, Bui V, Xin P, Wang N, Pan W. Intracellular Localization of the Tumor Suppressor HtrA1/Prss11 and its Association With HPV16 E6 and E7 Proteins. J Cell Biochem 2008; 105: 81-8.
171. Chien J, Ota T, Aletti G, et al. Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration. Mol Cell Biol 2009; 29: 4177-87.
172. Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-24.
173. He X, Khurana A, Maguire JL, Chien J, Shridhar V. HtrA1 sensi-tizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. Int J Cancer 2012; 130: 1029-35
174. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-85.
175. Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem 2008; 41: 561-9.
176. Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G. Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol 2006; 103: 253-60.
177. Narkiewicz J, Lapinska-Szumczyk S, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. Oncol Rep 2009; 21: 1529-37.
178. Mullany SA, Mosemi-Kebria M, Rattan R, et al. Expression and Functional Significance of HtrA1 loss in Endometrial Cancer. Clin Cancer Res 2010; 17: 427-36.
179. Zhu F, Jin L, Luo TP, Luo GH, Tan Y, Qin XH. Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobil-iary Pancreat Dis Int 2010; 9: 508-12.
180. Baldi A, De Luca A, Morini M, et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 2002; 21: 6684-8.
181. Esposito V, Campioni M, De Luca A, et al. Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res 2006; 26: 3455-9.
182. Spugnini EP, Cardillo I, Verdina A, et al. Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. Clin Cancer Res 2006; 12: 6133-43.
183. Catalano V, Mellone P, d’AvinoA, et al. HtrA1, a potential predic-tor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 2011; 58: 669-78.
184. Hu S-I, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 1998; 273: 34406-12.
185. Grau S, Richards PJ, Keer B, et al. The Role of Human HtrA1 in Arthritic Disease. J Biol Chem 2006; 281: 6124-9.
186. Tsuchiya A, Yano M, Tocharus J, et al. Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregu-lation in joint cartilage damaged by experimental arthritis. Bone 2005; 37: 323-36.
187. van der Kraan PM, Davidson ENB, Blom A, van den Berg WB. TGF-beta signaling in chondrocyte terminal differentiation and os-teoarthritis. Osteoarthritis Cartilage 2009; 17: 1539-45.
188. Hadfield KD, Rock CF, Inkson CA, et al. HtrA1 inhibits mineral deposition by osteoblasts: requirement for the protease and PDZ domains. J Biol Chem 2008; 283: 5928-38.
189. Hara K, Shiga A, Fukutake T, et al. Association of HtrA1 Mutations and Familial Ischemic Cerebral Small-Vessel Disease. N Engl J Med 2009; 360: 1729-39.
190. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest 2010; 120: 3033-41.
191. DeWan A, Liu M, Hartman S, et al. HTRA1 Promoter Polymor-phism in Wet Age-Related Macular Degeneration. Science 2006; 314: 989-92.
192. Kondo N, Hoda S, Ishibashi K, Tsukahara Y, Negi A. LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopa-thy and Age-related Macular Degeneration in a Japanese Popula-tion. Am J Ophthalmol 2007; 144: 605-12.
193. Yoshida T, DeWan A, et al. HTRA1 promoter polymorphism pre-disposes Japanese to age-related macular degeneration. Mol Vis 2007; 13: 545-8.
194. Cameron DJ, Yang Z, Gibbs D, et al. HTRA1 variant confers simi-lar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle 2007; 6:1122-5.
195. DeAngelis MM, Ji F, et al. Alleles in the HtrA serine protease 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology 2008; 115:1209-15.
196. Tong Y, Liao J, Zhang Y, Zhou J, Zhang H, Mao M. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis. Mol Vis 2010; 16: 1958-81.
197. Goto A, Akahori M, Okamoto H, et al. Genetic analysis of typical wet-type age-realetd maular degeneration and polypoidal choroidal vasculopathy in Japanese population. J Ocul Biol Dis Inform 2009; 2: 164-75.
198. Ng C, Chatwood S, Young TK. Arthritis in the Canadian Aborigi-nal population: North-South differences in prevalence and corre-lates. Chronic Dis Can 2010; 3: 22-6.
199. Yang Z, Camp N, Sun H, et al. A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degradation. Science 2006; 314: 992-3.
200. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007; 104: 16227-32.
201. Kanda A, Stambolian D, Chen W, Curcio CA, Abecasis GR, Swaroop A. Age-related macular degeneration-associated variants at chromosome 10q26 do not significantly alter ARMS2 and HTRA1 transcript levels in the human retina. Mol Vis 2010; 16: 1317-23.
202. Chowers I, Meir T, Lederman M, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in population from Israel. Mol Vis 2008; 14: 2263-71.
203. Friedrich U, Myers CA, Fritche LG, et al. Risk-and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency. Hum Mol Genet 2011; 20: 1387-99.
204. An E, Sen S, Park SK, Gordish-Dressman H, Hathout Y. Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome. Invest Ophthalmol Vis Sci 2010; 51: 3379-86.
205. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008; 40: 892-6.
206. Yang Z, Tong Z, Chen Y, et al. Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration. PLoS Genet 2010; 6: e1000836.
207. Faccio L, Fusco C, Chen A, Martinotti S, Bonventre JV, Zervos AS. Characterization of a novel human serine protease that has ex-tensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 2000; 275: 2581-8.
208. Gray CW, Ward RV, Karran E, et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 2000; 267: 5699-710.
209. Faccio L, Fusco C, Viel A, Zervos AS. Tissue-specific splicing of Omi stress-regulated endoprotease leads to an inactive protease with a modified PDZ motif. Genomics 2000; 68: 343-7.
210. Kadomatsu T, Mori M, Terada K. Mitochondrial import of Omi: the definitive role of the putative transmembrane region and multiple processing sites in the amino-terminal segment. Biochem Biophys Res Commun 2007; 361: 516-21.
211. Chao JR, Parganas E, Boyd K, Hong CY, Opferman JT, Ihle JN. Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature 2008; 452: 98-102.
212. Whitworth AJ, Lee JR, Ho VMW, Flick R, Chowdhury R, McQuibban A. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis Mod Mech 2008; 1: 168-74.
213. Marabese M, Mazzoletti M, Vikhanskaya F, Broggini M. HtrA2 enhances the apoptotic functions of p73 on bax. Cell Death Differ 2008; 15: 849-58.
214. Nam MK, Seong YM, Park HJ, Choi JY, Kang S, Rhim H. The homotrimeric structure of HtrA2 is indispensable for executing its serine protease activity. Exp Mol Med 2006; 38: 36-43.
215. Martins LM, Turk BE, Cowling V, et al. Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. J Biol Chem 2003; 278: 49417-27.
216. Zhang Y, Appleton BA, Wu P, Wiesmann C, Sidhu SS. Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain. Protein Sci 2007; 16: 1738-50.
217. Kuninaka S, Nomura M, Hirota T, et al. The tumor suppressor WARTS activates the Omi/HtrA2-dependent pathway of cell death. Oncogene 2005; 24: 5287-98.
218. Hong SK, Cha MK, Kim IH. Specific protein interaction of human Pag with Omi/HtrA2 and the activation of the protease activity of Omi/HtrA2. Free Rad Biol Med 2006; 40: 275-84.
219. Seong YM, Choi JY, Park HJ, et al. Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP. J Biol Chem 2004; 279: 37588-96.
220. Muñoz-Pienedo C, Guío-Carrión A, Goldstein JC, Fitzgerald P, Newmeyer DD, Green DR. Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is co-ordinately initiated but can vary in duration. Proc Natl Acad Sci USA 2006; 103: 11573-8.
221. Cilenti L, Soundarapandian MM, Kyriazis GA, et al Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem 2004; 279: 50295-301.
222. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apopto-sis. Genes Dev 2003; 17: 1487-96.
223. Srinivasula SM, Gupta S, Datta P, et al. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003; 278: 31469-72.
224. Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV, Cheng JQ. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212. J Biol Chem 2007; 282: 10981-7.
225. Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem 2011; 286: 37368-78.
226. Blink E, Maianski NA, Alnemri ES, Zervos AS, Roos D, Kuijpers TW. Intramitochondrial serine protease activity of Omi/HtrA2 is required for caspase-independent cell death of human neutrophils. Cell Death Differ 2004; 11: 937-9.
227. McCormick AL, Roback L, Mocarski ES. HtrA2/Omi terminates cytomegalovirus infection and is controlled by the viral mitochon-drial inhibitor of apoptosis (vMIA). PLoS Pathog 2008; 4: e1000063.
228. Hartkamp J, Roberts SG. The role of the Wilms' tumour-suppressor protein WT1 in apoptosis. Biochem Soc Trans 2008; 36: 629-31.
229. Tun C, Guo W, Nguyen H, et al. Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis. J Neurochem 2007; 102; 1206-19.
230. Iwasaki R, Ito K, Ishida T, et al. Catechin, green tea component, causes caspase-independent necrosis-like cell death in chronic myelogenous leukemia. Cancer Sci 2009; 100: 349-56.
231. Moisoi N, Klupsch K, Fedele V, et al. Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ 2009; 16: 449-64.
232. Gerhardt E, Gräber S, Szego EM, et al. Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS One 2011; 6: e28855.
233. Liu ML, Liu MJ, Kim JM, Kim HJ, Kim JH, Hong ST. HtrA2 interacts with A beta peptide but does not directly alter its production or degradation. Mol Cells 2005; 20: 83-9.
234. Plun-Favreau H, Klupsch K, Moisoi N, et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007; 9: 1243-52.
235. Fitzgerald JC, Camprubi MD, Donn L, et al. Phosphorylation of HtrA2 by Cyclin Dependent Kinase 5 is important for mitochon-drial function. Cell Death Differ 2012; 19: 257-66.
236. Plun-Favreau H, Gandhi S, Wood-Kaczmar A, Deas E, Yao Z, Wood NW. What have PINK1 and HtrA2 genes told us about the role of mitochondria in Parkinson's disease? Ann N Y Acad Sci. 2008; 1147: 30-6.
237. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14: 2099-111.
238. Bogaerts V, Nuytemans K, Reumers J, et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat 2008; 29: 832-40.
239. Lin CH, Chen ML, Chen GS, Tai CH, Wu RM. Novel variant Pro143Ala in HTRA2 contributes to Parkinson’s disease by induc-ing hyperphosphorylation of HTRA2 protein in mitochondria. Hum Genet 2011; 130: 817-27.
240. Kieper N, Holmström KM, Ciceri D, et al. Modulation of mito-chondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Exp Cell Res 2010; 316(7): 1213-24.
241. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43: 67–93.
242. Li B, Hu Q, Wang H, Man N, et al. Omi/HtrA2 is a positive regula-tor of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death Differ 2010; 17: 1773-84.
243. Liu ML, Liu MJ, Shen YF, et al. Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-beta. J Cell Sci 2009; 122: 1917-26.
244. Huttunen HJ, Guénette SY, Peach C, et al. HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. J Biol Chem 2007; 282: 28285-95.
245. Sorlie T, Tibshirani, R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
246. Yang X, Xing H, Gao Q, et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 2005; 97: 413-21.
247. Hu XY, Xu YM, Chen XCh, Ping H, Chen ZH, Zeng FQ. Immu-nohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. Acta Pathol Microbiol Immu-nol Scand 2006; 114: 893-8.
248. Zhu ZH, Yu YP, Zheng ZL, et al. Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death. Am J Pathol 2010; 177: 1176-86.
249. Lee SH, Lee JW, Kim HS, et al. Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. APMIS 2003; 111: 586-90.
250. Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse D, Perlman EJ; Renal Tumor Committee of the Children's Oncology Group. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005; 11: 7986-94.
251. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64: 55-63.
252. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia sub-groups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937-49.
253. Andersson A, Ritz C, Lindgren D, et al. Microarray-based classifi-cation of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198-203.
254. Li S, Wan M, Cao X, Ren Y. Expression of AIF and HtrA2/Omi in small lymphocytic lymphoma and diffuse large B-Cell lymphoma. Arch Pathol Lab Med 2011; 135: 903-8.
255. Baou M, Kohlhaas SL, Butterworth M, et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 2010; 95: 1510-8.
256. Théoleyre S, Mottier S, Masson D, Denis MG. HtrA3 is regulated by 15-deoxy-∆12,14-prostaglandin J2 independently of PPARγ in clear cell renal cell carcinomas. Biochem Biophys Res Commun 2010; 394: 453-8.
257. Singh H, Makino S, Endo Y, Li Y, Stephens AN, Nie G. Applica-tion of the wheat-germ cell-free translation system to produce high temperature requirement A3 (HtrA3) proteases. Biotechniques 2012; 52: 23-8.
258. Nie GY, Li Y, Minoura H, et al. A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with placentation. Mol Hum Reprod 2003; 9: 279-90.
259. Nie G, Li Y, Hale K, et al. Serine peptidase HTRA3 is closely associated with human placental development and is elevated in pregnancy serum. Biol Reprod 2006; 74: 366-74.
260. Li Y, Puryer M, Lin E, et al. Placental HtrA3 Is Regulated by Oxygen Tension and Serum Levels Are Altered during Early Pregnancy in Women Destined to Develop Preeclampsia. J Clin Endocrinol Metab 2011; 96: 403-11.
261. Chien J, He X, Shridhar V. Identification of Tubulins as Substrates of Serine Protease HtrA1 by Mixture-Based Oriented Peptide Li-brary Screening. J Cell Biochem 2009; 107: 253-63.
262. Hao Y, Triadafilopoulos G, Sahbaie P, YoungHS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barret’s esophagus and adenocarci-noma. Gastroenterology 2006; 131: 925-33.
263. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Patrol 2003; 102: 1151-62.
264. Korkola JE, Houldsworth J, Chadalavada RS, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006; 66: 820-7.
265. Baron C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010; 13: 100-5.
266. Sekine K, Hao Y, Suzuki Y, Takahashi R, Tsuruo T, Naito M. HtrA2 cleaves Apollon and induces cell death by IAP-binding motif in Apollon-deficient cells. Biochem Biophys Res Commun 2005; 330: 279-85.
267. Cilenti L, Kyriazis GA, Soundarapandian MM, et al. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 2005; 288: F371-9.
268. Kaminska B, Wesolowska A, Danilkiewicz M. TGF-beta signaling and its role in tumour pathogenesis. Acta Biochim Polon 2005; 52: 329-37.
269. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-94.
270. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apop-tosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-49.
271. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005; 65: 2378-86.
272. Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 2004; 35: 1022-8.
273. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-803.
274. Hartkamp J, Carpenter B, Roberts SG. The Wilms' tumor suppres-sor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell 2010; 37: 159-71.
275. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1-17.
276. Ross OA, Soto AI, Vilariño-Güell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 539-43.
277. Simón-Sánchez J, Singleton AB. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 2008; 17: 1988-93.
278. Krüger R, Sharma M, Riess O, et al. Genetic Epidemiology of Parkinson's disease consortium. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 2011; 32: 548.e9-18.
279. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alz-heimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 2003; 161: 41-54.
280. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheertha-varada HK. Accumulation of amyloid precursor protein in the mi-tochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci 2006; 26: 9057-68.
281. Behbahani H, Shabalina IG, Wiehager B, et al. Differential role of Presenilin-1 and-2 on mitochondrial membrane potential and oxygen consumption in mouse embryonic fibroblasts. J Neurosci Res 2006; 84: 891-902.
282. Blass JP. Metabolic alterations common to neural and non-neural cells in Alzheimer's disease. Hippocampus 1993; 3: 45-53.
283. Pavlov PF, Wiehager B, Sakai J, et al. Mitochondrial γ-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J 2011; 25: 78-88.
284. Grau S, Baldi A, Bussani R, et al. Implications of the serine prote-ase HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci USA 2005; 102: 6021-6.
285. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA. Discovery of an allosteric site in the caspases. Proc Natl Acad Sci USA 2004; 101: 12461-6.
286. Groebe DR. Screening for positive allosteric modulators of bio-logical targets. Drug Discov Today 2006; 11: 632-9.
287. Zhang Y, Appleton BA, Wiesmann C, et al. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat Chem Biol 2009; 5: 217-9.
288. Hammond MC, Harris BZ, Lim WA, Bartlett PA. Beta strand pep-tidomimetics as potent PDZ domain ligands. Chem Biol 2006; 13: 1247-51.
289. Fujii N, Haresco JJ, Novak KA, et al. Rational design of a nonpep-tide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorg Med Chem Lett 2007; 17: 549-52.
290. Lewis JA, Lebois EP, Lindsley CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr Opin Chem Biol 2008; 12: 269-80.
291. Lowman HB, Chen YM, Skelton NJ, et al. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry 1998; 37: 8870-8.
292. Zhu YF, Wang XC, Connors P, et al. Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. Bioorg Med Chem Lett 2003; 13: 1931-4.
293. Chen C, Zhu YF, Liu XJ, Lu ZX, Xie Q, Ling N. Discovery of a series of nonpeptide small molecules that inhibit the binding of in-sulin-like growth factor (IGF) to IGF-binding proteins. J Med Chem 2001; 44: 4001-10.
294. Cilenti L, Lee Y, Hess S, et al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem 2003; 278: 11489-94.
295. Liu HR, Gao E, Hu A, et al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2005; 111: 90-6.
296. Su D, Su Z, Wang J, Yang S, Ma J. UCF-101, a novel Omi/HtrA2 inhibitor, protects against cerebral ischemia/reperfusion injury in rats. Anat Rec (Hoboken) 2009; 292: 854-61.
297. Klupsch K, Downward J. The protease inhibitor Ucf-101 induces cellular responses independently of its known target, HtrA2/Omi. Cell Death Differ. 2006; 13: 2157-9.
298. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Science 1995; 4: 337-360.
299. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777-81.
300. Campioni M, Severino A, Manente L, et al. The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein. Mol Cancer Res 2010; 8: 1248-60.
301. Vande Walle L, Van Damme P, Lamkanfi M, et al. Proteome-wide Identification of HtrA2/Omi Substrates. J Proteome Res 2007; 6: 1006-15.
302. Radke S, Chander H, Schäfer P, Meiss G, Krüger R, Schulz JB, Germain D. Mitochondrial protein quality control by the protea-some involves ubiquitination and the protease Omi. J Biol Chem 2008; 283: 12681-5.
303. Johnson F, Kaplitt MG. Novel mitochondrial substrates of Omi indicate a new regulatory role in neurodegenerative disorders. PLoS One 2009; 4: e7100.
304. Park HM, Kim GZ, Nam MK, et al. The serine protease HtrA2/Omi cleaves Parkin and irreversibly inactivates its E3 ubiq-uitin ligase activity. Bioch Biophys Res Commun 2009; 387: 537-42.
305. Park DW, Nam MK, Rhim H. The serine protease HtrA2 cleaves UCH-L1 and inhibits its hydrolase activity: Implication in UCH-L1 cell death. Biochem Biophys Res Commun 2011; 415: 24-9.
306. Oka Z, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-90.